MICROBA LIFE SCIENCES LIMITED — Board/Management Information 2025

Nov 11, 2025

ASX Announcement 12 November 2025

==> picture [171 x 52] intentionally omitted <==

Board Renewal

Microba Life Sciences Limited (ASX: MAP) (“Microba” or “the Company”) today announces a number of planned changes to its Board of Directors as part of a Board renewal process. These changes strengthen Microba’s position as the Company continues to deliver on its global commercialisation strategy and accelerates the growth of its microbiome testing business across key markets.

Key Highlights

• Mr Stéphane Chatonsky to be appointed as an Independent Non-Executive Director, effective 20 November 2025.

• Non-Executive Directors Mr Richard Bund and Dr Hyungtae Kim to retire at the 2025 Annual General Meeting (AGM) on 19 November 2025, after more than six years of service each.

Appointment of Stéphane Chatonsky

The Company is pleased to announce the appointment of Mr Stéphane Chatonsky as an Independent NonExecutive Director, effective 20 November 2025.

Mr Chatonsky brings over 25 years of experience in venture capital, investment and corporate strategy, focused on high-growth healthcare, pathology and technology businesses. He has held various senior roles with Lazard, McKinsey & Company, Macquarie Bank, 4Cyte Pathology, Healius and LeapFrog Investments, and currently serves as a Non-Executive Director of Cerulea Clinical Trials and NeoBionica, and is a Senior Advisor to Heidi Health and Vexev. He holds an MBA from the Wharton School, a Bachelor of Economics from ESSEC Business School (Paris), and is a Graduate of the Australian Institute of Company Directors.

His deep commercial acumen and governance expertise will further strengthen the Board’s capability as Microba continues to accelerate its growth globally.

The Board welcomes Mr Chatonsky and looks forward to his contribution to Microba’s next phase of growth.

Director Retirements

The Company advises that Mr Richard Bund and Dr Hyungtae Kim will retire from the Board at the 2025 AGM on 19 November 2025. Both Mr Bund and Dr Kim remain supportive of Microba, its leadership and strategic direction as the Company advances its next phase of growth.

Mr Bund has served as a Non-Executive Director since 2018 and has made a significant contribution to Microba’s governance and strategic evolution. He chaired the Nomination and Remuneration Committee and was a member of the Audit and Risk Committee. Mr Bund has played a key role in guiding the Company through its early commercialisation phase and its successful transition to a listed entity in 2022.

Dr Kim joined the Board in 2019 as a representative of Macrogen Inc., which provided strategic and financial support to Microba through its formative years. His scientific and international perspective have been invaluable as the Company developed and expanded its core microbiome technology platform.

The Board sincerely thanks Mr Bund and Dr Kim for their dedication, leadership and service to Microba over the past seven years.

==> picture [78 x 133] intentionally omitted <==

==> picture [61 x 61] intentionally omitted <==

JOIN MICROBA’S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

ASX Announcement 12 November 2025

==> picture [171 x 52] intentionally omitted <==

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer luke.reid@microba.com

Investor / Media Relations

investor@microba.com https://ir.microba.com/welcome

About Microba Life Sciences Limited

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com

==> picture [61 x 61] intentionally omitted <==

JOIN MICROBA’S INTERACTIVE INVESTOR HUB

==> picture [78 x 133] intentionally omitted <==

For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621